S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:ATRC

AtriCure (ATRC) Stock Price, News & Analysis

$30.14
+1.05 (+3.61%)
(As of 03/27/2024 ET)
Today's Range
$29.09
$30.47
50-Day Range
$28.21
$37.78
52-Week Range
$27.92
$59.61
Volume
841,359 shs
Average Volume
655,324 shs
Market Capitalization
$1.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.57

AtriCure MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
84.4% Upside
$55.57 Price Target
Short Interest
Bearish
6.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of AtriCure in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$423,212 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.71) to ($0.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.88 out of 5 stars

Medical Sector

636th out of 939 stocks

Surgical & Medical Instruments Industry

64th out of 96 stocks

ATRC stock logo

About AtriCure Stock (NASDAQ:ATRC)

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Stock Price History

ATRC Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
AtriCure (NASDAQ:ATRC) Downgraded by StockNews.com
AtriCure (NASDAQ:ATRC) Reaches New 12-Month Low at $28.21
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
StockNews.com Upgrades AtriCure (NASDAQ:ATRC) to Hold
ATRC Apr 2024 22.500 put
AtriCure (ATRC) Fell on Competitor Action
AtriCure Full Year 2023 Earnings: EPS Beats Expectations
AtriCure price target raised by $1 at UBS, here's why
Cracking The Code: Understanding Analyst Reviews For AtriCure
Recap: AtriCure Q4 Earnings
AtriCure Q4 2023 Earnings Preview
AtriCure's Earnings: A Preview
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/27/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
1,200
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$55.57
High Stock Price Target
$68.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+84.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-30,440,000.00
Pretax Margin
-7.48%

Debt

Sales & Book Value

Annual Sales
$399.24 million
Book Value
$9.84 per share

Miscellaneous

Free Float
46,924,000
Market Cap
$1.46 billion
Optionable
Optionable
Beta
1.39

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

ATRC Stock Analysis - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price target for 2024?

5 Wall Street research analysts have issued twelve-month price objectives for AtriCure's shares. Their ATRC share price targets range from $42.00 to $68.00. On average, they anticipate the company's stock price to reach $55.57 in the next year. This suggests a possible upside of 84.4% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2024?

AtriCure's stock was trading at $35.69 at the start of the year. Since then, ATRC shares have decreased by 15.6% and is now trading at $30.14.
View the best growth stocks for 2024 here
.

Are investors shorting AtriCure?

AtriCure saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,970,000 shares, an increase of 25.3% from the February 29th total of 2,370,000 shares. Based on an average daily trading volume, of 618,100 shares, the short-interest ratio is presently 4.8 days.
View AtriCure's Short Interest
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ATRC earnings forecast
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) posted its quarterly earnings data on Thursday, February, 15th. The medical device company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. The medical device company had revenue of $106.50 million for the quarter, compared to the consensus estimate of $103.68 million. AtriCure had a negative trailing twelve-month return on equity of 7.55% and a negative net margin of 7.62%. AtriCure's revenue for the quarter was up 21.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.09) EPS.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of -0.820--0.740 for the period, compared to the consensus earnings per share estimate of -0.690. The company issued revenue guidance of $459.0 million-$466.0 million, compared to the consensus revenue estimate of $455.9 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?
Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.05%), Vanguard Group Inc. (10.01%), First Light Asset Management LLC (2.85%), Wellington Management Group LLP (2.79%), Nuveen Asset Management LLC (2.16%) and Dimensional Fund Advisors LP (2.11%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends
.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AtriCure have any subsidiaries?
The following companies are subsidiares of AtriCure: SentreHEART.
Read More
This page (NASDAQ:ATRC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners